• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

    12/13/23 1:40:34 PM ET
    $ABM
    $BLBX
    $BQ
    $CALM
    Diversified Commercial Services
    Consumer Discretionary
    EDP Services
    Technology
    Get the next $ABM alert in real time by email

    Shares of Despegar.com, Corp. (NYSE:DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance.

    The company said it now sees revenue of $690 million to $700 million, versus previous forecast of $670 million to $700 million.

    Despegar.com shares gained 16.4% to $9.90 on Wednesday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Shattuck Labs, Inc. (NASDAQ:STTK) jumped 127.5% to $4.80 after the company announced initial topline dose-expansion data from its ongoing Phase 1A/B clinical trial of SL-172154 in combination with AZA in frontline HR-MDS and TP53m AML patients.
    • ReShape Lifesciences Inc. (NASDAQ:RSLS) shares gained 63.8% to $0.4110 after the company announced it received FDA PMA supplement approval for its next-generation Lap-Band 2.0 FLEX.
    • C4 Therapeutics, Inc. (NASDAQ:CCCC) shares jumped 59% to $3.7199 after the company announced data from the CFT7455 Phase 1 trial in relapsed/refractory multiple myeloma. Following the update, Stifel analyst Bradley Canino upgraded C4 Therapeutics from Hold to Buy and raised the price target from $2 to $12.
    • RiskOn International, Inc. (NASDAQ:ROI) shares gained 38.3% to $0.2016 after declining 9% on Tuesday.
    • Innovative International Acquisition Corp. (NASDAQ:IOAC) shares rose 36% to $11.66.
    • NextPlay Technologies, Inc. (NASDAQ:NXTP) shares gained 26% to $1.1708 after surging 29% on Tuesday.
    • Nephros, Inc. (NASDAQ:NEPH) rose 23% to $3.16.
    • SciSparc Ltd. (NASDAQ:SPRC) gained 21.7% to $5.95 after the company announced results for MitoCareX Bio with its drug discovery platform.
    • Eos Energy Enterprises, Inc. (NASDAQ:EOSE) rose 21% to $1.35. Eos Energy and Pine Gate Renewables announced partnership expansion with a minimum additional volume Of 500MWH.
    • Photronics, Inc. (NASDAQ:PLAB) gained 18.7% to $25.66 following fourth-quarter results.
    • Mynaric AG (NASDAQ:MYNA) shares surged 18.2% to $5.66 after the company received a $33 million order from Northrop Grumman.
    • QuantaSing Group Limited (NASDAQ:QSG) rose 17.2% to $2.4380 following first-quarter results.
    • Professional Diversity Network, Inc. (NASDAQ:IPDN) gained 16% to $2.8899.
    • Aurora Mobile Limited (NASDAQ:JG) shares gained 14% to $2.8254. Aurora Mobile said its subsidiary Wuhan SendCloud Technology Co., Ltd. has entered into a strategic partnership with Beijing Muhua Information Technology Co., Ltd.
    • ABM Industries Incorporated (NYSE:ABM) surged 13.6% to $50.38 after the company reported better-than-expected fourth-quarter financial results and issued guidance.
    • LQR House Inc. (NASDAQ:LQR) rose 9.5% to $1.4126. LQR House announced its new marketing campaign for Soda Jerk.
    • Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) gained 7.4% to $384.03 after the company announced results from its Phase 2 study of VX-548 for the treatment of painful diabetic peripheral neuropathy.
    • REV Group, Inc. (NYSE:REVG) gained 7.3% to $18.31 following upbeat quarterly results.
    • Cal-Maine Foods, Inc. (NASDAQ:CALM) rose 6.3% to $51.96. Cal-Maine has temporarily ceased production at a facility in Kansas following an outbreak of avian influenza at the site.
    • Take-Two Interactive Software, Inc. (NASDAQ:TTWO) shares rose 3.5% to $162.64. Take-Two will be added to the Nasdaq-100 Index, effective prior to market open on Monday, Dec. 18, 2023.

    Losers

    • Hywin Holdings Ltd. (NASDAQ:HYW) shares fell 46.6% to $3.0001.
    • Boqii Holding Limited (NYSE:BQ) declined 33.3% to $0.6670.
    • Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) fell 32.2% to $0.5497 as the company announced outcomes from meeting with the FDA regarding the company's next Phase 2 study supporting the advancement of next generation capecitabine for cancer patients.
    • Loop Media, Inc. (NASDAQ:LPTV) fell 28.3% to $0.9246 following fourth-quarter results.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) declined 27% to $0.1415. TC BioPharm announced plan to implement ADS ratio change.
    • SRIVARU Holding Limited (NASDAQ:SVMH) fell 25.5% to $0.3051.
    • Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) fell 24.6% to $0.2637.
    • Green Giant Inc. (NASDAQ:GGE) fell 18.8% to $0.0690. Green Giant recently announced pricing of its public offering.
    • WANG & LEE GROUP, Inc. (NASDAQ:WLGS) fell 16.2% to $0.46 after gaining 7% on Tuesday.
    • Blackboxstocks Inc. (NASDAQ:BLBX) fell 15.8% to $3.24. Blackboxstocks announced it executed a definitive agreement to acquire Evtec Aluminium Limited.
    • IN8bio, Inc. (NASDAQ:INAB) shares fell 10.8% to $1.46 after jumping 28% on Tuesday. IN8bio recently announced updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies.
    • Target Hospitality Corp. (NYSE:TH) declined 11% to $9.74 as the company lowered its FY23 guidance.
    • Medifast, Inc. (NYSE:MED) fell 9% to $68.66. LifeMD announced a strategic alliance with Medifast to offer transformative weight management solution.
    • Pfizer Inc. (NYSE:PFE) declined 8.8% to $26.07 after the company provided FY24 guidance.
    • JetBlue Airways Corporation (NASDAQ:JBLU) fell 6.2% to $5.20.
    • Southwest Airlines Co. (NYSE:LUV) fell 6% to $28.51. Southwest Airlines sees fourth-quarter unit revenues to be down 9%-10% vs. prior view of down 9%-11%.

     

    Now Read This: Don't Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts

    Get the next $ABM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABM
    $BLBX
    $BQ
    $CALM

    CompanyDatePrice TargetRatingAnalyst
    Southwest Airlines Company
    $LUV
    4/24/2026$36.10Reduce → Hold
    HSBC Securities
    JetBlue Airways Corporation
    $JBLU
    4/16/2026$8.00Neutral → Buy
    Seaport Research Partners
    JetBlue Airways Corporation
    $JBLU
    3/24/2026$4.50Market Perform
    BMO Capital Markets
    Photronics Inc.
    $PLAB
    3/20/2026$46.00Buy
    Lake Street
    Vertex Pharmaceuticals Incorporated
    $VRTX
    3/18/2026$575.00Hold → Buy
    Maxim Group
    Target Hospitality Corp.
    $TH
    3/17/2026$11.00Perform → Outperform
    Oppenheimer
    ABM Industries Incorporated
    $ABM
    3/11/2026$50.00Hold → Buy
    Maxim Group
    Vertex Pharmaceuticals Incorporated
    $VRTX
    3/10/2026$580.00Buy
    Jefferies
    More analyst ratings

    $ABM
    $BLBX
    $BQ
    $CALM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Southwest Airlines Company

    DEFA14A - SOUTHWEST AIRLINES CO (0000092380) (Filer)

    4/24/26 4:52:37 PM ET
    $LUV
    Air Freight/Delivery Services
    Consumer Discretionary

    SEC Form EFFECT filed by Aurora Mobile Limited

    EFFECT - Aurora Mobile Ltd (0001737339) (Filer)

    4/24/26 12:15:12 AM ET
    $JG
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SCHEDULE 13D/A filed by JetBlue Airways Corporation

    SCHEDULE 13D/A - JETBLUE AIRWAYS CORP (0001158463) (Subject)

    4/23/26 4:55:25 PM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    $ABM
    $BLBX
    $BQ
    $CALM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President St George Martin J converted options into 46,882 shares and covered exercise/tax liability with 23,934 shares, increasing direct ownership by 23% to 120,857 units (SEC Form 4) (withholding tax)

    4 - JETBLUE AIRWAYS CORP (0001158463) (Issuer)

    4/23/26 5:13:58 PM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    SEC Form 4 filed by General Counsel Corp Sec Mccarthy Eileen P

    4 - JETBLUE AIRWAYS CORP (0001158463) (Issuer)

    4/23/26 5:13:14 PM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    SEC Form 4 filed by Chief Financial Officer Hurley Ursula L

    4 - JETBLUE AIRWAYS CORP (0001158463) (Issuer)

    4/23/26 5:13:07 PM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    $ABM
    $BLBX
    $BQ
    $CALM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABM
    $BLBX
    $BQ
    $CALM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aurora Mobile's GPTBots.ai Integrates DeepSeek-V4 Preview, Bringing Million-Token Context and Next-Generation Agentic AI to Enterprise Users

    HONG KONG, April 24, 2026 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ:JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services, today announced that its enterprise-grade AI agent platform, GPTBots.ai, has integrated the newly released DeepSeek-V4 Preview series. This integration delivers immediate, production-ready access to one of the most capable open-source AI models available today—combining DeepSeek-V4's breakthrough long-context processing and frontier agentic performance with GPTBots.ai's enterprise-grade security, no-code deployment, and intelligent workflow orchestration. DeepSeek-V4: A New Frontier in Open-Source

    4/24/26 7:00:00 AM ET
    $JG
    Computer Software: Programming Data Processing
    Technology

    Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

    Expands Options for Cash-Paying Patients to Access the Nation's #1 Prescribed Oral Blood Thinner The Bristol Myers Squibb-Pfizer (NYSE:BMY) — (NYSE:PFE) Alliance today announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to offer Eliquis® (apixaban) on CostPlusDrugs.com. Eliquis is one of the most widely prescribed oral anticoagulants in the United States and one of the largest brands in the space to be offered on the site, which allows patients to purchase prescription medicines directly at reduced costs, providing another avenue for patients to access the medication. "The BMS-Pfizer Alliance is pleased to expand our direct-to-patient options

    4/24/26 6:59:00 AM ET
    $BMY
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Target Hospitality Announces Closing of Secondary Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    THE WOODLANDS, Texas, April 23, 2026 /PRNewswire/ -- Target Hospitality Corp. ("Target Hospitality" or the "Company") (NASDAQ:TH), one of North America's largest providers of vertically-integrated modular accommodations and value-added hospitality services, today announced that it has closed its previously announced underwritten, secondary offering (the "Offering") of 8,050,000 shares of its common stock, par value $0.0001 per share (the "Common Stock"), held by Arrow Holdings S.à r.l. and MFA Global S.à r.l. (collectively, the "Selling Stockholders"), entities controlled by TDR Capital LLP, acting in its capacity as investment fund manager, at a price to the public of $14.00 per share, incl

    4/23/26 5:00:00 PM ET
    $TH
    Hotels/Resorts
    Consumer Discretionary

    $ABM
    $BLBX
    $BQ
    $CALM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Urban David bought $100,100 worth of shares (16,250 units at $6.16), increasing direct ownership by 35% to 62,471 units (SEC Form 4)

    4 - Eos Energy Enterprises, Inc. (0001805077) (Issuer)

    3/10/26 8:52:43 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Chief Executive Officer Mastrangelo Joe bought $157,262 worth of shares (23,900 units at $6.58), increasing direct ownership by 2% to 1,487,126 units (SEC Form 4)

    4 - Eos Energy Enterprises, Inc. (0001805077) (Issuer)

    3/5/26 8:48:21 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Director Dimitrief Alexander bought $90,600 worth of shares (15,000 units at $6.04), increasing direct ownership by 7% to 235,221 units (SEC Form 4)

    4 - Eos Energy Enterprises, Inc. (0001805077) (Issuer)

    3/4/26 8:56:17 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    $ABM
    $BLBX
    $BQ
    $CALM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Southwest Air upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Southwest Air from Reduce to Hold and set a new price target of $36.10

    4/24/26 8:02:05 AM ET
    $LUV
    Air Freight/Delivery Services
    Consumer Discretionary

    JetBlue Airways upgraded by Seaport Research Partners with a new price target

    Seaport Research Partners upgraded JetBlue Airways from Neutral to Buy and set a new price target of $8.00

    4/16/26 8:06:55 AM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    BMO Capital Markets initiated coverage on JetBlue Airways with a new price target

    BMO Capital Markets initiated coverage of JetBlue Airways with a rating of Market Perform and set a new price target of $4.50

    3/24/26 8:40:25 AM ET
    $JBLU
    Air Freight/Delivery Services
    Consumer Discretionary

    $ABM
    $BLBX
    $BQ
    $CALM
    Leadership Updates

    Live Leadership Updates

    View All

    Nephros Expands Strategic Focus in Greater New York Market with Dedicated Regional Leadership

    SOUTH ORANGE, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced an expansion of its strategic focus in the Greater New York City region with the addition of Dana Cunningham as a dedicated regional sales leader. The Greater New York market represents one of the most densely populated and infrastructure-intensive regions in the United States, with a high concentration of healthcare facilities, aging water systems, and increasing regulatory and operational focus on waterborne pathogen risk. Based on internal estimates, Nephros believes this region repre

    4/16/26 9:57:04 AM ET
    $NEPH
    Medical/Dental Instruments
    Health Care

    TalentAlly, a Subsidiary of Professional Diversity Network, Inc., Launches Next-Generation Career Fair Hiring Platform Powered by ByteCompute.ai

    CHICAGO, April 06, 2026 (GLOBE NEWSWIRE) -- Professional Diversity Network, Inc. (NASDAQ:IPDN) ("IPDN" or the "Company") today announced that its subsidiary, TalentAlly, has launched a next-generation platform, a comprehensive virtual hiring solution powered by ByteCompute.ai. The platform is designed to deliver measurable improvements in candidate engagement, recruiter efficiency, and hiring outcomes across virtual, in-person, and hybrid career events. With more than 12 years of experience in career fairs and recruitment solutions, the Company has supported over 1,300 employers and facilitated connections for more than half a million candidates. The launch of the platform represents the

    4/6/26 9:00:00 AM ET
    $IPDN
    Computer Software: Programming Data Processing
    Technology

    Cal-Maine Foods Welcomes Dudley D. Wooley to Board of Directors

    RIDGELAND, Miss., April 01, 2026 (GLOBE NEWSWIRE) -- Cal-Maine Foods, Inc. (NASDAQ:CALM), the largest egg company in the United States and a leading player in the egg-based food industry, today announced the appointment of Dudley D. Wooley to its Board of Directors. Mr. Wooley brings extensive leadership experience in risk management, business strategy, and governance, further strengthening the Board's depth of expertise as the Company continues executing its long-term growth strategy. Mr. Wooley currently serves as Chief Executive Officer of Ross & Yerger Insurance, Inc., a super-regional, employee-owned independent insurance agency headquartered in Jackson, Mississippi. With more than t

    4/1/26 6:00:00 AM ET
    $CALM
    Farming/Seeds/Milling
    Consumer Staples

    $ABM
    $BLBX
    $BQ
    $CALM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Eos Energy Enterprises Inc.

    SC 13D/A - Eos Energy Enterprises, Inc. (0001805077) (Subject)

    12/17/24 2:48:02 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Amendment: SEC Form SC 13D/A filed by Wheeler Real Estate Investment Trust Inc.

    SC 13D/A - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Subject)

    12/9/24 5:54:19 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABM
    $BLBX
    $BQ
    $CALM
    Financials

    Live finance-specific insights

    View All

    Eos Energy Enterprises Announces Date for First Quarter 2026 Financial Results and Conference Call; Announces Participation at Upcoming Investor Conferences

    EDISON, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ:EOSE) ("Eos" or the "Company"), an American energy company and the leading innovator in designing, sourcing, manufacturing, and providing zinc-based battery energy storage systems (BESS) manufactured in the United States, today announced it will release its first quarter 2026 financial results before the U.S. market opens on May 13, 2026. A conference call to discuss its results will take place the same morning at 8:30 a.m. Eastern Time. Eos partners with Say Technologies to allow retail and institutional shareholders to submit and vote on questions ahead of the earnings call. A selection of key question

    4/23/26 4:30:00 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    Take-Two Interactive Software, Inc. to Report Fourth Quarter and Fiscal Year 2026 Results on Thursday, May 21, 2026

    Take-Two Interactive Software, Inc. (NASDAQ:TTWO) today announced that it plans to report financial results for its fourth quarter and fiscal year 2026, ended March 31, 2026, after the market close on Thursday, May 21, 2026. The Company plans to hold a conference call to discuss its results at 4:30 p.m. Eastern Time, which can be accessed by dialing (800) 715-9871 or (646) 307-1963 (conference ID: 9711440). A live, listen-only webcast and a replay of the call will be available at http://take2games.com/ir. About Take-Two Interactive Software Headquartered in New York City, Take-Two Interactive Software, Inc. is a leading developer, publisher, and marketer of interactive entertainment for

    4/23/26 8:00:00 AM ET
    $TTWO
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Pfizer Declares Second-Quarter 2026 Dividend

    Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the company's common stock, payable June 12, 2026, to holders of the Common Stock of record at the close of business on May 8, 2026. The second-quarter 2026 cash dividend will be the 350th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, dev

    4/22/26 4:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care